Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 23, Issue 23, Pages 6377-6389Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2013.09.058
Keywords
FTY720; S1P(1)-R agonists; S1P(1)-R antagonists; Autoimmune diseases
Categories
Funding
- NIMH NIH HHS [U54 MH084512] Funding Source: Medline
Ask authors/readers for more resources
The Sphingosine 1-phosphate receptor (S1P-R) signaling system has proven to be of biological and medical importance in autoimmune settings. S1P(1)-R is a validated drug target for multiple sclerosis (MS) for which FTY720 (Fingolimod), a S1P(1,3-5)-R pan-agonist, was recently approved as the first orally active drug for the treatment of relapsing-remitting MS. Transient bradycardia and long half-life are the FTY720 critical pitfalls. This review provides the latest advances on next-generation S1P(1)-R modulators from 2012 up to date, with an overview of the chemical structures, structure-activity relationships, and relevant biological and clinical properties. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available